1.Paintsil E, Martin R, Goldenthal A, Bhandari S, Andiman W, Ghebremichael M. Frequent Episodes of Detectable Viremia in HIV Treatment-Experienced Children is Associated with a Decline in CD4+ T-cells Over Time. Journal of AIDS & clinical research. 2016;7(4).
2.Hermans LE, Moorhouse M, Carmona S, et al. Effect of HIV–1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study. The Lancet Infectious Diseases. 2018;18(2):188–197.
3.Bernal E, Gomez JM, Jarrin I, et al. Low-Level Viremia Is Associated With Clinical Progression in HIV-Infected Patients Receiving Antiretroviral Treatment. Journal of acquired immune deficiency syndromes. 2018;78(3):329–337.
4.Pereira R, Ludwig DA, Mathew S, et al. Predicting Viral Failure in Human Immunodeficiency Virus Perinatally Infected Youth With Persistent Low-Level Viremia on Highly Active Antiretroviral Therapy. Journal of the Pediatric Infectious Diseases Society. 2018.
5.Joya C, Won SH, Schofield C, et al. Persistent Low-Level Viremia while on Antiretroviral Therapy is an Independent Risk Factor for Virologic Failure. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2019.
6.Esber A, Polyak C, Kiweewa F, et al. Persistent low level viremia predicts subsequent virologic failure. Is it time to change the 3rd 90? Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2018.
7.Dravid AN, Natrajan K, Kulkarni MM, et al. Discordant CSF/plasma HIV–1 RNA in individuals on virologically suppressive antiretroviral therapy in Western India. Medicine. 2018;97(8):e9969.
8.Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations. World Health Organization. Available at: https://www.who.int/hiv/pub/guidelines/keypopulations–2016/en/9789241511124-eng.pdf. Accessed July, 2016.
9.Pernas B, Rego-Perez I, Tabernilla A, et al. Plasma mitochondrial DNA levels are inversely associated with HIV-RNA levels and directly with CD4 counts: potential role as a biomarker of HIV replication. The Journal of antimicrobial chemotherapy. 2017;72(11):3159–3162.
10.Torres B, Guardo AC, Leal L, et al. Protease inhibitor monotherapy is associated with a higher level of monocyte activation, bacterial translocation and inflammation. Journal of the International AIDS Society. 2014;17(1):19246.
11.Swenson LC, Cobb B, Geretti AM, et al. Comparative performances of HIV–1 RNA load assays at low viral load levels: results of an international collaboration. Journal of clinical microbiology. 2014;52(2):517–523.
12.Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. Department of Health and Human Services. Available at: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Updated 2018 March 27. Accessed.
13.Pernas B, Grandal M, Pertega S, et al. Any impact of blips and low-level viraemia episodes among HIV-infected patients with sustained virological suppression on ART? The Journal of antimicrobial chemotherapy. 2016;71(4):1051–1055.
14.Maggiolo F, Callegaro A, Cologni G, et al. Ultrasensitive assessment of residual low-level HIV viremia in HAART-treated patients and risk of virological failure. Journal of acquired immune deficiency syndromes. 2012;60(5):473–482.
15.Ryom L, Boesecke C, Bracchi M, et al. Highlights of the 2017 European AIDS Clinical Society (EACS) Guidelines for the treatment of adult HIV-positive persons version 9.0. HIV medicine. 2018;19(5):309–315.
16.Zhang S, van Sighem A, Gras L, et al. Clinical significance of transient HIV type–1 viraemia and treatment interruptions during suppressive antiretroviral treatment. Antiviral therapy. 2010;15(4):555–562.
17.Grennan JT, Loutfy MR, Su D, et al. Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis. The Journal of infectious diseases. 2012;205(8):1230–1238.
18.Vandenhende MA, Perrier A, Bonnet F, et al. Risk of virological failure in HIV–1-infected patients experiencing low-level viraemia under active antiretroviral therapy (ANRS C03 cohort study). Antiviral therapy. 2015;20(6):655–660.
19.Laprise C, de Pokomandy A, Baril JG, Dufresne S, Trottier H. Virologic failure following persistent low-level viremia in a cohort of HIV-positive patients: results from 12 years of observation. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2013;57(10):1489–1496.
20.Henrich TJ, Wood BR, Kuritzkes DR. Increased risk of virologic rebound in patients on antiviral therapy with a detectable HIV load <48 copies/mL. PloS one. 2012;7(11):e50065.
21.Boillat-Blanco N, Darling KEA, Schoni-Affolter F, et al. Virological outcome and management of persistent low-level viraemia in HIV–1-infected patients: 11 years of the Swiss HIV Cohort Study. Antiviral therapy. 2014;20(2):165–175.
22.Farmer A, Wang X, Ganesan A, et al. Factors associated with HIV viral load “blips” and the relationship between self-reported adherence and efavirenz blood levels on blip occurrence: a case-control study. AIDS research and therapy. 2016;13:16.
23.Quiros-Roldan E, Raffetti E, Castelli F, et al. Low-level viraemia, measured as viraemia copy-years, as a prognostic factor for medium-long-term all-cause mortality: a MASTER cohort study. The Journal of antimicrobial chemotherapy. 2016;71(12):3519–3527.
24.Wright ST, Hoy J, Mulhall B, et al. Determinants of viremia copy-years in people with HIV/AIDS after initiation of antiretroviral therapy. Journal of acquired immune deficiency syndromes. 2014;66(1):55–64.
25.AIDS and Hepatitis C Professional Group SoID, Chinese Medical Association, Chinese Center for Disease Control and Prevention. Chinese guidelines for diagnosis and treatment of HIV/AIDS (2018). Zhonghua Nei Ke Za Zhi. 2018;57(12):867–884.
26.Ruggiero A, Cozzi-Lepri A, Beloukas A, et al. Factors Associated With Persistence of Plasma HIV–1 RNA During Long-term Continuously Suppressive Firstline Antiretroviral Therapy. Open Forum Infect Dis. 2018;5(2):ofy032.
27.Trickey A, May MT, Vehreschild JJ, et al. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet Hiv. 2017;4(8):E349-E356.
28.Szubert AJ, Prendergast AJ, Spyer MJ, et al. Virological response and resistance among HIV-infected children receiving long-term antiretroviral therapy without virological monitoring in Uganda and Zimbabwe: Observational analyses within the randomised ARROW trial. PLoS medicine. 2017;14(11):e1002432.
29.Gunthard HF, Calvez V, Paredes R, et al. Human Immunodeficiency Virus Drug Resistance: 2018 Recommendations of the International Antiviral Society-USA Panel. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2019;68(2):177–187.
30.Zaccarelli M, Santoro MM, Armenia D, et al. Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA. Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology. 2016;82:94–100.
31.Palmer S, Maldarelli F, Wiegand A, et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proceedings of the National Academy of Sciences of the United States of America. 2008;105(10):3879–3884.
32.Mutoh Y, Nishijima T, Inaba Y, et al. Incomplete Recovery of CD4 Cell Count, CD4 Percentage, and CD4/CD8 Ratio in Patients With Human Immunodeficiency Virus Infection and Suppressed Viremia During Long-term Antiretroviral Therapy. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2018;67(6):927–933.
33.Elvstam O, Medstrand P, Yilmaz A, Isberg PE, Gisslen M, Bjorkman P. Virological failure and all-cause mortality in HIV-positive adults with low-level viremia during antiretroviral treatment. PloS one. 2017;12(7):e0180761.
34.Antiretroviral Therapy Cohort C, Vandenhende MA, Ingle S, et al. Impact of low-level viremia on clinical and virological outcomes in treated HIV–1-infected patients. Aids. 2015;29(3):373–383.
35.Teira R, Vidal F, Munoz-Sanchez P, et al. Very low level viraemia and risk of virological failure in treated HIV–1-infected patients. HIV medicine. 2017;18(3):196–203.
36.Sorstedt E, Nilsson S, Blaxhult A, et al. Viral blips during suppressive antiretroviral treatment are associated with high baseline HIV–1 RNA levels. BMC Infect Dis. 2016;16:305.